Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMDW267)

Drug Name

9-Methoxy-5,11-dimethyl-6H-pyrido[4,3-b]carbazole Drug Info

Synonyms

9-Methoxyellipticine; Methoxyelliptione; Methoxyellipticine; 9-Methoxyellipticin; 9-Methoxy-5,11-dimethyl-6H-pyrido[4,3-b]carbazole; 10371-86-5; ICI 180 base; Ellipticine, 9-methoxy-; AT 181; ICIG 772; NSC69187; NSC 69187; B 656501 K003; 9-Methoxy-Ellipticine; UNII-U0924292N9; EINECS 233-812-0; BRN 0279742; 9-Methoxy-5,11-dimethyl-6H-pyrido(4,3-b)carbazole; CHEMBL19954; MLS000736760; C18H16N2O; BKRMCDAOAQWNTG-UHFFFAOYSA-N; NSC-69187; 6H-Pyrido[4,3-b]carbazole, 9-methoxy-5,11-dimethyl-; 6H-Pyrido(4,3-b)carbazole, 5,11-dimethyl-9-me

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 72512
CAS Number: CAS 10371-86-5
TTD Drug ID: DMDW267

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Tyrosine-protein kinase Kit (KIT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[2]
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[3]
Romiplostim	DM3U7SZ	Thrombocytopenia	3B64	Approved	[4]
Regorafenib	DMHSY1I	Gastrointestinal stromal tumour	2B5B	Approved	[5]
Ponatinib	DMYGJQO	Acute lymphoblastic leukaemia	2A85	Approved	[5]
Pazopanib HCl	DM6U9CQ	Renal cell carcinoma	2C90	Approved	[6]
Pexidartinib	DMS2J0Z	Tenosynovial giant cell tumour	2F7B	Approved	[7]
Ripretinib	DM958QB	Gastrointestinal stromal tumour	2B5B	Approved	[8]
Famitinib	DMSFWT7	Solid tumour/cancer	2A00-2F9Z	Phase 2	[9]
XL-820	DMMHX9K	Solid tumour/cancer	2A00-2F9Z	Phase 2	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Tyrosine-protein kinase Kit (KIT)	TTX41N9	KIT_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Molecular modeling of wild-type and D816V c-Kit inhibition based on ATP-competitive binding of ellipticine derivatives to tyrosine kinases. J Med Chem. 2005 Oct 6;48(20):6194-201.
2	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
3	Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling.Mol Cancer Ther.2008 Oct;7(10):3129-40.
4	New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven a... J Med Chem. 2000 Jun 15;43(12):2310-23.
5	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
6	Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
7	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
8	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
9	Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol. 2013 Apr;168(7):1687-706.
10	National Cancer Institute Drug Dictionary (drug id 452042).